Thermo Fisher Scientific Inc. $TMO Shares Acquired by MGO One Seven LLC

Key Points

• MGO One Seven LLC increased its stake in Thermo Fisher Scientific Inc. by 26.7%, owning 3,204 shares valued at approximately $1.3 million as per the latest SEC filing.
• Thermo Fisher reported an earnings per share (EPS) of $5.36, surpassing estimates, and revenue of $10.86 billion for the quarter, indicating a year-over-year increase of 2.9%.
• Analysts have set an average price target of $589.10 for Thermo Fisher's stock, with 15 investment analysts recommending a "Buy" rating.

MGO One Seven LLC lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 26.7% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,204 shares of the medical research company's stock after acquiring an additional 676 shares during the period. MGO One Seven LLC's holdings in Thermo Fisher Scientific were worth $1,299,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the stock. Cypress Capital Group acquired a new stake in shares of Thermo Fisher Scientific during the second quarter valued at $479,000. Bill Few Associates Inc. boosted its stake in Thermo Fisher Scientific by 6.3% in the 2nd quarter. Bill Few Associates Inc. now owns 588 shares of the medical research company's stock worth $238,000 after buying an additional 35 shares during the last quarter. Hazlett Burt & Watson Inc. boosted its stake in Thermo Fisher Scientific by 15.3% in the 2nd quarter. Hazlett Burt & Watson Inc. now owns 1,760 shares of the medical research company's stock worth $714,000 after buying an additional 233 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in Thermo Fisher Scientific by 2.0% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 106,999 shares of the medical research company's stock worth $45,097,000 after buying an additional 2,062 shares during the last quarter. Finally, GW Henssler & Associates Ltd. boosted its stake in Thermo Fisher Scientific by 0.9% in the 2nd quarter. GW Henssler & Associates Ltd. now owns 37,057 shares of the medical research company's stock worth $15,025,000 after buying an additional 347 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

Shares of NYSE:TMO opened at $527.34 on Thursday. The company has a market cap of $199.13 billion, a P/E ratio of 30.50, a PEG ratio of 2.85 and a beta of 0.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $610.97. The business's 50-day simple moving average is $492.55 and its 200 day simple moving average is $448.75.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company's revenue was up 2.9% on a year-over-year basis. During the same period last year, the business posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the sale, the chief accounting officer directly owned 2,319 shares in the company, valued at $1,142,408.97. The trade was a 14.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $500.50, for a total value of $200,200.00. Following the sale, the chief executive officer owned 113,762 shares in the company, valued at $56,937,881. This represents a 0.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,066 shares of company stock worth $14,182,963 in the last three months. 0.33% of the stock is owned by insiders.

Analysts Set New Price Targets

TMO has been the topic of a number of research analyst reports. Redburn Partners set a $580.00 price target on Thermo Fisher Scientific in a research note on Wednesday, October 8th. Raymond James Financial reissued an "outperform" rating and issued a $535.00 price target (up from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. UBS Group raised their price target on Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a research note on Thursday, July 24th. Robert W. Baird lifted their price objective on Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a research note on Thursday, July 24th. Finally, JPMorgan Chase & Co. lifted their price objective on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an "overweight" rating in a research note on Thursday, October 9th. Fifteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $589.10.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.